Cg Oncology (CGON) Stock
Cg Oncology (CGON) has a Tenet Score of 54 of 100 against 297 Healthcare peers, as of Nov 13, 2026.
32 figures withheld by our checks. Each blank figure names its reason.
Key stats
- Market cap
- $6.6B
- share price × the latest quarter's diluted weighted-average share count (vendor)
- 52-week range
- 37.01 – 80.97
- low → high · as of close, Nov 13, 2026
- Tenet Score
- 54/100
- Mixed · 297 Healthcare peers
Industry: Biological Products, Except Diagnostic Substances
Cg Oncology Inc. scores 54/100. Mixed. Strongest on financial health, value is the soft spot versus 297 Healthcare peers. Insufficient inputs: Tenet 54 is built from 3 of 4 pillars, from 40% of its inputs. The pillars showing a dash had no data.
Tenet Score · vs sector
n=297Factor grades
Growth omitted — no data yet.
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ✕ Buffett Quality
- ✕ Piotroski F-Score
- ✕ Graham Defensive
- ✕ Drawdown Context
- ✕ Reversal Evidence
- ✕ Quality Floor
We are a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Our product candidate, cretostimogene, is initially in clinical dev…
Similar-sized companies in Biological Products, Except Diagnostic Substances
The 1 company in this industry closest in market cap, as of Nov 13, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| Inhibrx Biosciences Inc.INBX | 44 | $1.2B |
Common questions
What sector and industry is Cg Oncology in?
Cg Oncology is in the Healthcare sector and the Biological Products, Except Diagnostic Substances industry.
What is Cg Oncology's Tenet Score?
Cg Oncology's Tenet Score is 54 out of 100, ranked against 297 Healthcare peers as of Nov 13, 2026.




